0 486

Cited 11 times in

Optimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio

DC Field Value Language
dc.contributor.author구교철-
dc.contributor.author나군호-
dc.contributor.author이광석-
dc.contributor.author이종수-
dc.contributor.author정병하-
dc.contributor.author하지수-
dc.contributor.author홍성준-
dc.contributor.author한경석-
dc.contributor.author하윤수-
dc.date.accessioned2019-12-18T01:00:39Z-
dc.date.available2019-12-18T01:00:39Z-
dc.date.issued2019-
dc.identifier.issn0724-4983-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/173320-
dc.description.abstractPURPOSE: To investigate the prognostic value of neutrophil-to-lymphocyte ratio (NLR) for the selection of the optimal sequencing strategy using docetaxel and androgen receptor axis-targeted (ARAT) agents in patients with M0 or M1 castration-resistant prostate cancer (CRPC). Currently, there is a need to identify biomarkers to guide optimal sequential treatment in CRPC. METHODS: This multicenter, retrospective analysis included 303 consecutive patients initially diagnosed with M0 or M1 CRPC between September 2009 and March 2017. Of these, 52 (17.2%) patients received pre-docetaxel ARAT agents and 189 (62.4%) patients received post-docetaxel ARAT agents. The prognostic ability of NLR at CRPC diagnosis regarding radiographic progression-free survival (rPFS) and cancer-specific survival (CSS) were investigated. For the analysis, the NLR level was dichotomized at 2.5, and evaluated according to sequencing strategy. RESULTS: Multivariate analysis revealed NLR ≥ 2.5 as an independent predictor of a lower risk for CSS. During the median follow-up of 18.5 months, patients with NLR ≥ 2.5 exhibited significantly lower 1-year rPFS (p = 0.011) and 2-year CSS rates (p = 0.005) compared to patients with NLR < 2.5. Among patients with NLR < 2.5, the post-docetaxel ARAT agent sequencing group exhibited higher 1-year rPFS (p = 0.031) and 2-year CSS (p = 0.026) rates compared to the pre-docetaxel ARAT agent sequencing group. Among patients with NLR ≥ 2.5, rPFS and CSS rates were comparable regardless of ARAT agent sequencing. CONCLUSION: NLR ≥ 2.5 at CRPC diagnosis is associated with a lower risk for CSS. Patients with NLR < 2.5 should primarily be offered docetaxel considering the survival benefit of docetaxel-to-ARAT agent sequencing.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherSpringer International-
dc.relation.isPartOfWORLD JOURNAL OF UROLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleOptimal sequencing strategy using docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant prostate cancer: utilization of neutrophil-to-lymphocyte ratio-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Urology (비뇨의학교실)-
dc.contributor.googleauthorKyo Chul Koo-
dc.contributor.googleauthorJong Soo Lee-
dc.contributor.googleauthorJee Soo Ha-
dc.contributor.googleauthorKyung Suk Han-
dc.contributor.googleauthorKwang Suk Lee-
dc.contributor.googleauthorYoon Soo Hah-
dc.contributor.googleauthorKoon Ho Rha-
dc.contributor.googleauthorSung Joon Hong-
dc.contributor.googleauthorByung Ha Chung-
dc.identifier.doi10.1007/s00345-019-02658-1-
dc.contributor.localIdA00188-
dc.contributor.localIdA01227-
dc.contributor.localIdA02668-
dc.contributor.localIdA05500-
dc.contributor.localIdA03607-
dc.contributor.localIdA05527-
dc.contributor.localIdA04402-
dc.relation.journalcodeJ02805-
dc.identifier.eissn1433-8726-
dc.identifier.pmid30734074-
dc.identifier.urlhttps://link.springer.com/article/10.1007%2Fs00345-019-02658-1-
dc.subject.keywordCastration resistant-
dc.subject.keywordDocetaxel-
dc.subject.keywordLymphocytes-
dc.subject.keywordNeutrophils-
dc.subject.keywordProstatic neoplasms-
dc.subject.keywordSurvival-
dc.contributor.alternativeNameKoo, Kyo Chul-
dc.contributor.affiliatedAuthor구교철-
dc.contributor.affiliatedAuthor나군호-
dc.contributor.affiliatedAuthor이광석-
dc.contributor.affiliatedAuthor이종수-
dc.contributor.affiliatedAuthor정병하-
dc.contributor.affiliatedAuthor하지수-
dc.contributor.affiliatedAuthor홍성준-
dc.citation.volume37-
dc.citation.number11-
dc.citation.startPage2375-
dc.citation.endPage2384-
dc.identifier.bibliographicCitationWORLD JOURNAL OF UROLOGY, Vol.37(11) : 2375-2384, 2019-
dc.identifier.rimsid63633-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.